Xeris Biopharma Holdings (LTS:0A8E) ROCE % : -18.97% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Xeris Biopharma Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was -18.97%.

Xeris Biopharma Holdings ROCE % Historical Data

The historical data trend for Xeris Biopharma Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings ROCE % Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-124.15

-75.82

-64.86

-33.04

-14.81

Xeris Biopharma Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-16.63	-22.88	-9.28	-11.29	-18.97

Xeris Biopharma Holdings ROCE % Calculation

Xeris Biopharma Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-36.895	/	( ( (344.522 - 73.621)	+	(322.602 - 95.193) )	/ 2 )
	=	-36.895	/	( (270.901	+	227.409)	/ 2 )
	=	-36.895	/	249.155
	=	-14.81 %

Xeris Biopharma Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-46.564	/	( ( (322.602 - 95.193)	+	(336.616 - 73.084) )	/ 2 )
	=	-46.564	/	( ( 227.409	+	263.532 )	/ 2 )
	=	-46.564	/	245.4705
	=	-18.97 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Xeris Biopharma Holdings (LTS:0A8E) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Xeris Biopharma Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings (LTS:0A8E) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

XERS:USA 2B30:Germany

Address

180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

Xeris Biopharma Holdings (LTS:0A8E) Headlines

No Headlines